MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,171 INR | -0.52% |
|
-6.96% | +9.52% |
| Sales 2024 * | 103B 1.24B 98.97B | Sales 2025 * | 117B 1.4B 112B | Capitalization | 874B 10.48B 839B |
|---|---|---|---|---|---|
| Net income 2024 * | 18.3B 219M 17.56B | Net income 2025 * | 21.75B 261M 20.88B | EV / Sales 2024 * | 8.23 x |
| Net cash position 2024 * | 25.25B 303M 24.24B | Net cash position 2025 * | 43.42B 520M 41.68B | EV / Sales 2025 * | 7.12 x |
| P/E ratio 2024 * |
47.7
x | P/E ratio 2025 * |
40.1
x | Employees | 18,468 |
| Yield 2024 * |
0.31% | Yield 2025 * |
0.44% | Free-Float | 19.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mankind Pharma Limited
More recommendations
| 1 day | +0.43% | ||
| 1 week | -6.07% | ||
| Current month | -7.29% | ||
| 1 month | -7.33% | ||
| 3 months | -2.22% | ||
| 6 months | +20.63% | ||
| Current year | +10.57% |
1 week
2 145.00
2 353.25
1 month
2 145.002 490.00
Current year
1 980.002 490.00
1 year
1 242.002 490.00
3 years
1 242.002 490.00
5 years
1 242.002 490.00
10 years
1 242.002 490.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 48 | 20/09/07 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 55 | 16/06/16 |
Pradeep Chugh
CMP | Compliance Officer | - | 22/09/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vivek Kalra
BRD | Director/Board Member | 60 | 31/07/22 |
Vijaya Sampath
BRD | Director/Board Member | 71 | 31/07/22 |
Surendra Lunia
BRD | Director/Board Member | 61 | 18/02/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 2,171 | -0.52% | 456 258 |
| 08/05/24 | 2,183 | -1.56% | 454,898 |
| 07/05/24 | 2,217 | -3.04% | 407,210 |
| 06/05/24 | 2,287 | -1.22% | 485,808 |
| 03/05/24 | 2,315 | -0.81% | 227,950 |
Delayed Quote NSE India S.E., May 09, 2024 at 09:56 am
More quotes
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,183
INR
Average target price
2,186
INR
Spread / Average Target
+0.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.57% | 10.48B | |
| +32.95% | 698B | |
| +26.51% | 568B | |
| -4.97% | 358B | |
| +18.83% | 328B | |
| +3.54% | 283B | |
| +15.87% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +6.70% | 165B |
- Stock Market
- Equities
- MANKIND Stock
